Learn more The iShares Core High Dividend ETF (NYSEMKT: HDV) isn't as large or as popular as other dividend ETFs. As a result ...
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology ...
Discover 5 top Big Pharma stocks amid rising cancer, type 2 diabetes and IMIDs—dividend yields, earnings beats and why they ...
1d
These are the best stocks in the worst sectors for investors betting on a rotation, says Josh Brown
That's an extremely healthy tape and we love to see it. While the gains of 2026 have obviously been in tech stocks away from ...
The tables have turned for the U.S. biosimilars market. With more than a decade since the first FDA biosim approval, strong launches to biologic copies to AbbVie’s Humira, J&J’s Stelara and ...
For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism ...
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell ...
A U.S. senator is pressing pharmaceutical giant Merck over its patenting and pricing practices for the blockbuster cancer drug Keytruda, escalating congressional scrutiny of industry strategies that ...
Merck & Co., Inc. (NYSE:MRK) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June 25, Merck & Co., Inc.
Merck (NYSE: MRK) closed Tuesday's session down 0.87% at $128.26, breaking a six-session winning streak. The stock had gained 13.62% over the preceding six trading sessions, outperforming the S&P 500, ...
Sen. Maggie Hassan is pressing pharmaceutical giant Merck over access and cost issues around one of its most popular and best ...
On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results